MARABio key facts
as of Oct 2026- Provider of maternal autoantibody-related autism testing intended to determine the risk of autism spectrum disorder (ASD).
- MARABio is valued at approximately $34.1M as of Oct 2026 (last reported valuation).
- It has raised $26.8M; the latest was Later Stage VC ($20.8M) in Jan 2025.
- Notable investors include MAK Capital, AIF, Mesa Verde Venture Partners, Moai Capital.
- Status: Privately Held (backing).
MARABio's last reported valuation, Jan 2025. Nothing priced has surfaced since.
- ·Watch MARABio: the Monday email on marks, rounds and moves
MARABio funding rounds
No funding rounds for MARABio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs MARABio
4MARABio valuation
MARABio's last reported valuation was $34.1 million in Jan 2025. No priced round, secondary trade or fund mark has surfaced since.
MARABio investors
4 investors are on record for MARABio, including MAK Capital, AIF, Mesa Verde Venture Partners and Moai Capital.
About MARABio
Provider of maternal autoantibody-related autism testing intended to determine the risk of autism spectrum disorder (ASD). The company develops a precision technology that is capable of identifying an unusual and distinctive cluster of antibodies that are directed against proteins in the developing brain of mothers whose children are diagnosed with ASD, enabling mothers to initiate specific beneficial behavioral therapies much earlier if their children exhibit signs of developmental delay.
- Sector
- Healthcare
- HQ
- Salt Lake City, UT, United States
- Founded
- 2016
- Employees
- 10
- Website
- marabio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.